BMS-986020 selectively inhibits the LPA receptor, which is involved in binding of the signaling molecule lysophosphatidic acid, which in turn is involved in a host of diverse biological functions like cell proliferation, platelet aggregation, smooth muscle contraction, chemotaxis, and tumor cell invasion, among others.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO: ≥ 50 mg/mL|
Lysophospholipid receptors in drug discovery.
Kihara Y, et al. Exp Cell Res. 2015 May 1;333(2):171-7. PMID: 25499971.
|Related LPL Receptor Products|
|AM095 free acid
AM095 free acid is a potent LPA1 receptor antagonist which inhibited GTPγS binding to CHO cell membranes overexpressing recombinant human or mouse LPA1 with IC50 values of 0.98 and 0.73 μM, respectively.
AM966 is a potent, selective and orally active LPA(1) receptor antagonist which inhibits lung fibrosis in the mouse bleomycin model.
AM095 is a potent and selective, orally bioavailable antagonist of lysophosphatidic acid receptor1 (LPA1).
Ki16425 is a LPA receptor antagonist with Ki values of 0.34, 6.5 and 0.93 μM for the human LPA1, LPA2 and LPA3 receptors, respectively.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.